China Pharma Holdings (CPHI) Raw Materials (2017 - 2024)

China Pharma Holdings (CPHI) has reported Raw Materials for 8 consecutive years, with $869820.0 the latest figure, recorded in Q3 2024.

• For the quarter ending Q3 2024, Raw Materials fell 53.69% year-over-year to $869820.0; the trailing twelve-month figure through Sep 2024 stood at $869820.0 (down 53.69% YoY), and the FY2023 full-year result was $1.8 million, up 0.52% from the prior year.
• Raw Materials fell to $869820.0 in Q3 2024 per CPHI's latest filing, from $1.2 million in the prior quarter.
• Across five years, Raw Materials topped out at $2.2 million in Q1 2023 and bottomed at $869820.0 in Q3 2024.
• Historically, Raw Materials has averaged $1.8 million across 5 years, with a median of $1.8 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Raw Materials climbed 20.5% in 2023, then tumbled 53.69% in 2024.
• Over 5 years, Raw Materials stood at $2.1 million in 2020, then fell by 11.63% to $1.8 million in 2021, then changed by 0.0% to $1.8 million in 2022, then climbed by 0.52% to $1.8 million in 2023, then tumbled by 52.96% to $869820.0 in 2024.
• According to Business Quant data, Raw Materials over the past three periods registered $869820.0, $1.2 million, and $1.7 million for Q3 2024, Q2 2024, and Q1 2024 respectively.